{"ticker": {"uuid": "ea41eaf0-aab0-4a09-b5a9-572aceec438c", "symbol": "1801", "name": "Innovent Biologics, Inc.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Innovent stock trades steadily as oncology pipeline and revenue growth support valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZThiMGxLLXc5ak5JRl9GeXhsVHZtTXg1NFItYjkwbWpmRDhZMW5MSHdUNG9vdkFLd0w0TjYyaHpGYlRYNWNtdU45SWc5bjhvRGFHbWhnbVNKdTIxcEhSR1BNTThIMWk0YkhrRU1WQmFRbWRpODc5VlBjckpWcGYtWWtqRVVpYUp6UVFDRk1ZX0g4bHNvbmp4YTZjZGVPRUo5OTZ3T3dia3BWckJNcUctbVdHOTJ3YWFPb1lDWGQ1emJBaXd6RUt4bg?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-17T14:07:22+00:00", "published_display": "17 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T14:48:27+00:00", "published_display": "16 Jul 2026 14:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T02:22:08+00:00", "published_display": "12 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Innovent Biologics (SEHK:1801) Valuation After Strong Long Term Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbEljVW5WZ0ZtbUVJbU9ScW53c3dfYmtqM0VJSVNJZG93RDI5b3dkMkdRQ3dnNDduSGRwR01YcnFxREo1a25mOExLRjhXb2p1alpSX1E1ZlVkQ2puUWRqWF91aktTR1RycHdTMUpYM2I5RWxwVTM1dU1GamdqVGtldmFKUFhFWnNlTEN4LWVBcUpLWGN0d3k5aXBWbEx5SW9tb2ltd3NWUHNMYTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Innovent Biologics (SEHK:1801) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWkxmaU51bS1uNjFMN1ZLZUlqbW9MN0lnSjRKTlEtaGVJdmEtRlpyUmczOHJWbFVrc0xza1dic2JUMTdqYXlHX09XbnJmUTNWc1BuTmhLNFdrd1BGWHNZSGFNdE1ucndaX09kUHBCelhmSmlGXzdKY2dfdWRrWlhIMk02LUE1TmFJOXZuV3ZWTlNDbE9oLWZ3UGdOMml3Z0JSTVVYY2s1NFFfNFU?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent\u2019s IBI-302 meets phase III endpoints in neovascular AMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNQ1VGWEVyblZuWThORU1CWkhQZ3NPdk9BcEdyLXNNRHE5QkZNbDJEaU9UUzNKaUlRVDBGcHRzbVNjb2JrT2lTcXBSbGtROHQwZi1vZUpwU2FJT2JkbzJfekJsZ1ZxNGNnZklSZXVfVTJpQUNqVkFDejZzSmJ0Z1dXMmVDY0dkNHZETm16U0tWQ05TMXVQNHJjd2h2aGJyRDhweGwzT01n?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Shares Jump on First Profit, Obesity Drug Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOT2lYNUlESngtVlR2TnVXdVNqVW1hNXVYNHZSUVdCZHQzaGFyT3l0Q05vZS11aGpQOEVmMDY4Rm9QbEFfUmticW9XMm1IblNFTHhvUXZDcDZobDlxS1BSR0pYNEt6eUxjcFRXZDBFcnNwUHlpX1ROQk5WS1FlNHNyamp3OVVkeGxoa2hfY2V0TEQzek84LTFSa25QazZDZGs5MWt2a1BvNGRVeGtTcFE?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent-Lilly $8.5B deal signals new China inflection point", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQ2o3dS1aY0g5a1h5TEFZcFJSREY5bEh4eW96WndmcWVxcXRnZjYxQ3FrUDdvY2ZRTUpOWTFva2FNREpOVU55QW1YWUtMQzFSVkp3VTNZN0hsbDhrYkpvRnB0dEFzaEZNZ254VHVDY3B0VTFsRE1SVXhfbWU0RGw5cWJhX0dOaFV4SXc2QXBxMGZpQjBxVi11M3R5d2RNM24y?oc=5", "source_name": "BioWorld News", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "So big but so what? Innovent\u2019s license deal fails to excite investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRWY5eHBoRzU1bE90ZFBtM0VMVnlGZXE4Z3pVQm5rX0Qwc3E2aTZzdWpaYTdTWVFTM3hDWjBqWURzTW8yVjVob3cxdDNiRnFzMDNWWC1qZ3JuNi00SDlPd3NrN01OWWxSZnJ0NW9MNklFbi1IMF9XN3lQd2lMY0RwNEtjUjFHU003T2VkNmRRSVMya1JLOFR5dWg0VQ?oc=5", "source_name": "thebambooworks.com", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Strikes $11.4 Billion Cancer Drug Deal With Takeda", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQT0VuTm5COXQyNmJJbGdQRGVFeVRjT0pDLXJ4YjczRWpzU3hFMXlSUUtVelVRYXBaOVdjUHM0dGtZTjBONlZpR093WlVJdjlTc29aRFllaWQ2T1VrYXBoZC1ZcHlmTEtZOXhTd1MwamVJUzZaOTFqYTBMX3JSbVgzUGREUldPREZwdUVLUVJIRTBHVnBvc3BlYjRfYlFGdmZabDBjTXhFak9FSU1EUmtmbUh3?oc=5", "source_name": "Caixin Global", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New year, new $1B deal: Roche taps Innovent for new DLL3 ADC drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPM2JvOWhhMF9Nd3ZfbnVRR3ZxcjRlQ0hlRklPc0czM1VhREpidmotRnpHWEZjUUY5b1NJYm1hbVE3UzRmUlptTUtNWF94UUFDRzRDZDNqdU5TWGRQS3ZZeUsxYXlMUjItVy1sRnR0a3NuaVNacXgtWEo3TlNBb0huN1ZmMDJQUTlON1YxOUJuN3pOWTNUajhxdS1mLUc5WWZxUHJQS3lR?oc=5", "source_name": "BioWorld News", "published_at": "2025-01-07T08:00:00+00:00", "published_display": "07 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent ditches low-value stake sale after investor outcry", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOcTVSYzlGelB2M0dpUnJ4LVozMlVRS0hkeU9rRXZUb3lLaTJ4dDljSi1xUjNXMFNOc1lvaThxZFVhYlZrM2paVGc2c0VkQVpLQU9OMGNwZEZERmwtVldXRDJBZnhqbFpVWl9JaDYtWG9KalNfRFhpbWFTM2FhNVVCZUJSNURZY2VldVNmdTRjTk8?oc=5", "source_name": "thebambooworks.com", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Innovent Biologics secures over $300 million investment from Sanofi", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQNGFZTXhDTFdCd055NEFZc2N1eF9ZeTV3Mlg1b0lTbXphTXFfcUxnUWh2QUxLOXFnWWtLSllnaGlySkpyUTljdUtGV244ZEZ3UU96WEdDSmh6cV95Z3pqaFhSYWRkdWF0WVBGX2VRX24tQTJDRVkyT2ZUc2JCOHVDZm9FcFZ6NE1oUFUtNjB1SWVtSHZhQkZDcE5KRXVEMEt4UEpvODNpSGNpX0pXTzh0bGwtV1E0VjhUblc3TlRwOUhfYUVlTUVSRVdWMVllWWlqTUE?oc=5", "source_name": "Reuters", "published_at": "2022-08-04T07:00:00+00:00", "published_display": "04 Aug 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOMlpEM2pYZXVOdURYbEtBSGpJS0hZWlV6SEo2elVaamxCRndQcWlCa1FjVVpmbzdYc1Q2dTJrdkZFbV96NzBWSTdlbTFZWUZPSWozRU9GMnMwYkdJWkI0ME5XdTBsem9IUmZwZnVUTDMzQS1teU1qZTkwbEt4c0FkalRrZEJZWldacG5WQW5ocG02ZUM4N0drV1pFTmlMYWVKOF9DRmtCdHJjWWR0S3hnNmdkNExpbmtKbTFOMFowbWlOS2lWYjhZaWNDeXh4S3dzT28tQjlCS28tLTBva1kwWnNqbHd3R1EwRjVxRzl4cGNSeXNaVVowRENacEhMaGZOSWI3Q3o0OVdPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2019-02-27T08:00:00+00:00", "published_display": "27 Feb 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Innovent stock trades steadily as oncology pipeline and revenue growth support valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZThiMGxLLXc5ak5JRl9GeXhsVHZtTXg1NFItYjkwbWpmRDhZMW5MSHdUNG9vdkFLd0w0TjYyaHpGYlRYNWNtdU45SWc5bjhvRGFHbWhnbVNKdTIxcEhSR1BNTThIMWk0YkhrRU1WQmFRbWRpODc5VlBjckpWcGYtWWtqRVVpYUp6UVFDRk1ZX0g4bHNvbmp4YTZjZGVPRUo5OTZ3T3dia3BWckJNcUctbVdHOTJ3YWFPb1lDWGQ1emJBaXd6RUt4bg?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-17T14:07:22+00:00", "published_display": "17 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Biologics (SEHK:1801) Is Up 9.1% After Striking US$1.10 Billion IBI355 Licensing Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-16T14:48:27+00:00", "published_display": "16 Jul 2026 14:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T02:22:08+00:00", "published_display": "12 Jul 2026 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxPTUZCUENTT2t5TzJaYnp3ZnZWQ2RLYmhXYVdEeG9aVlRQeDdPX0d5WEE2MjQ0b2VBc0Q5S2JMMG9qOUdiUTFzMjZQNnZKV014Z3dkRU50Q0lEMjVUWUFKZEZDemQzeUdtYXQ0enZyZFY2VVJLaW8wZXpfUXFFdWJZQmhwSEpGUk4yZTliZFRFUWpSWGhrYTFCT2lJUzJyN1FtT2Q5Tm9yNU52b1FRSExVcVM1MkpGU1ljUFpfVDBCdEFqaF9WcUtYSmNVRnFONWp3OXQ5b2JNSHEydFRJUWl5WFFhMDJGeXQ5TmdkUNIB8gFBVV95cUxPZ1c5ekxjWnBHNVd6OFFmMUxwTWllUWtXYW1BekNpbGxDLUdPM3NUWl9aaGg3V0xvUTFHOUFxMnNaUmRJeDVvQUI4WFN6UWY0Z1Nic2VobXY0eDRrQmJSVG95X0h3UFhNcVFOS3FTNEZpUWMxZGJiNThzWUhGWUl6ZHRnSUlkb0dqTmhVaE55Y0VHQVlxN0Noa0Q4OFpNaUpnZXRJMk9kVk1hRmFweEJGQjE2RHBIWlY0cktqamczeEcwbEV5QWNNbzVubmxmaEtlVnhfTkx0ek9zLWI2VVE1YnZ0ZDFEZ3JTbnE2LUVuMEFzQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Innovent Biologics (SEHK:1801) Valuation After Strong Long Term Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbEljVW5WZ0ZtbUVJbU9ScW53c3dfYmtqM0VJSVNJZG93RDI5b3dkMkdRQ3dnNDduSGRwR01YcnFxREo1a25mOExLRjhXb2p1alpSX1E1ZlVkQ2puUWRqWF91aktTR1RycHdTMUpYM2I5RWxwVTM1dU1GamdqVGtldmFKUFhFWnNlTEN4LWVBcUpLWGN0d3k5aXBWbEx5SW9tb2ltd3NWUHNMYTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Innovent Biologics (SEHK:1801) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWkxmaU51bS1uNjFMN1ZLZUlqbW9MN0lnSjRKTlEtaGVJdmEtRlpyUmczOHJWbFVrc0xza1dic2JUMTdqYXlHX09XbnJmUTNWc1BuTmhLNFdrd1BGWHNZSGFNdE1ucndaX09kUHBCelhmSmlGXzdKY2dfdWRrWlhIMk02LUE1TmFJOXZuV3ZWTlNDbE9oLWZ3UGdOMml3Z0JSTVVYY2s1NFFfNFU?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent\u2019s IBI-302 meets phase III endpoints in neovascular AMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNQ1VGWEVyblZuWThORU1CWkhQZ3NPdk9BcEdyLXNNRHE5QkZNbDJEaU9UUzNKaUlRVDBGcHRzbVNjb2JrT2lTcXBSbGtROHQwZi1vZUpwU2FJT2JkbzJfekJsZ1ZxNGNnZklSZXVfVTJpQUNqVkFDejZzSmJ0Z1dXMmVDY0dkNHZETm16U0tWQ05TMXVQNHJjd2h2aGJyRDhweGwzT01n?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Shares Jump on First Profit, Obesity Drug Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOT2lYNUlESngtVlR2TnVXdVNqVW1hNXVYNHZSUVdCZHQzaGFyT3l0Q05vZS11aGpQOEVmMDY4Rm9QbEFfUmticW9XMm1IblNFTHhvUXZDcDZobDlxS1BSR0pYNEt6eUxjcFRXZDBFcnNwUHlpX1ROQk5WS1FlNHNyamp3OVVkeGxoa2hfY2V0TEQzek84LTFSa25QazZDZGs5MWt2a1BvNGRVeGtTcFE?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent-Lilly $8.5B deal signals new China inflection point", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQQ2o3dS1aY0g5a1h5TEFZcFJSREY5bEh4eW96WndmcWVxcXRnZjYxQ3FrUDdvY2ZRTUpOWTFva2FNREpOVU55QW1YWUtMQzFSVkp3VTNZN0hsbDhrYkpvRnB0dEFzaEZNZ254VHVDY3B0VTFsRE1SVXhfbWU0RGw5cWJhX0dOaFV4SXc2QXBxMGZpQjBxVi11M3R5d2RNM24y?oc=5", "source_name": "BioWorld News", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "So big but so what? Innovent\u2019s license deal fails to excite investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRWY5eHBoRzU1bE90ZFBtM0VMVnlGZXE4Z3pVQm5rX0Qwc3E2aTZzdWpaYTdTWVFTM3hDWjBqWURzTW8yVjVob3cxdDNiRnFzMDNWWC1qZ3JuNi00SDlPd3NrN01OWWxSZnJ0NW9MNklFbi1IMF9XN3lQd2lMY0RwNEtjUjFHU003T2VkNmRRSVMya1JLOFR5dWg0VQ?oc=5", "source_name": "thebambooworks.com", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Strikes $11.4 Billion Cancer Drug Deal With Takeda", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQT0VuTm5COXQyNmJJbGdQRGVFeVRjT0pDLXJ4YjczRWpzU3hFMXlSUUtVelVRYXBaOVdjUHM0dGtZTjBONlZpR093WlVJdjlTc29aRFllaWQ2T1VrYXBoZC1ZcHlmTEtZOXhTd1MwamVJUzZaOTFqYTBMX3JSbVgzUGREUldPREZwdUVLUVJIRTBHVnBvc3BlYjRfYlFGdmZabDBjTXhFak9FSU1EUmtmbUh3?oc=5", "source_name": "Caixin Global", "published_at": "2025-10-24T07:00:00+00:00", "published_display": "24 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New year, new $1B deal: Roche taps Innovent for new DLL3 ADC drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPM2JvOWhhMF9Nd3ZfbnVRR3ZxcjRlQ0hlRklPc0czM1VhREpidmotRnpHWEZjUUY5b1NJYm1hbVE3UzRmUlptTUtNWF94UUFDRzRDZDNqdU5TWGRQS3ZZeUsxYXlMUjItVy1sRnR0a3NuaVNacXgtWEo3TlNBb0huN1ZmMDJQUTlON1YxOUJuN3pOWTNUajhxdS1mLUc5WWZxUHJQS3lR?oc=5", "source_name": "BioWorld News", "published_at": "2025-01-07T08:00:00+00:00", "published_display": "07 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent ditches low-value stake sale after investor outcry", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOcTVSYzlGelB2M0dpUnJ4LVozMlVRS0hkeU9rRXZUb3lLaTJ4dDljSi1xUjNXMFNOc1lvaThxZFVhYlZrM2paVGc2c0VkQVpLQU9OMGNwZEZERmwtVldXRDJBZnhqbFpVWl9JaDYtWG9KalNfRFhpbWFTM2FhNVVCZUJSNURZY2VldVNmdTRjTk8?oc=5", "source_name": "thebambooworks.com", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Innovent Biologics secures over $300 million investment from Sanofi", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQNGFZTXhDTFdCd055NEFZc2N1eF9ZeTV3Mlg1b0lTbXphTXFfcUxnUWh2QUxLOXFnWWtLSllnaGlySkpyUTljdUtGV244ZEZ3UU96WEdDSmh6cV95Z3pqaFhSYWRkdWF0WVBGX2VRX24tQTJDRVkyT2ZUc2JCOHVDZm9FcFZ6NE1oUFUtNjB1SWVtSHZhQkZDcE5KRXVEMEt4UEpvODNpSGNpX0pXTzh0bGwtV1E0VjhUblc3TlRwOUhfYUVlTUVSRVdWMVllWWlqTUE?oc=5", "source_name": "Reuters", "published_at": "2022-08-04T07:00:00+00:00", "published_display": "04 Aug 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOMlpEM2pYZXVOdURYbEtBSGpJS0hZWlV6SEo2elVaamxCRndQcWlCa1FjVVpmbzdYc1Q2dTJrdkZFbV96NzBWSTdlbTFZWUZPSWozRU9GMnMwYkdJWkI0ME5XdTBsem9IUmZwZnVUTDMzQS1teU1qZTkwbEt4c0FkalRrZEJZWldacG5WQW5ocG02ZUM4N0drV1pFTmlMYWVKOF9DRmtCdHJjWWR0S3hnNmdkNExpbmtKbTFOMFowbWlOS2lWYjhZaWNDeXh4S3dzT28tQjlCS28tLTBva1kwWnNqbHd3R1EwRjVxRzl4cGNSeXNaVVowRENacEhMaGZOSWI3Q3o0OVdPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2019-02-27T08:00:00+00:00", "published_display": "27 Feb 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 87, "total_relevant": 15, "sentiment_summary": {"positive": 4, "negative": 0, "neutral": 11, "score": 56, "total": 15, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 4.2, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "earnings", "label": "Earnings", "weight": 1.45, "count": 2}], "positive_events": 4, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 89.7, "latest_week": "2026-07-10", "one_week_move": 2.2, "four_week_move": 17.3, "twelve_week_move": -2.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.405442, "market_dynamics_buy_signal": false, "relative_strength": 8.640806, "fair_value_gap": 55.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.5132, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.2% over one week, +17.3% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 3}, {"label": "BioWorld News", "count": 3}, {"label": "Market source", "count": 2}, {"label": "thebambooworks.com", "count": 2}, {"label": "ad-hoc-news.de", "count": 1}, {"label": "Bloomberg.com", "count": 1}, {"label": "Caixin Global", "count": 1}, {"label": "Reuters", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 7}, {"label": "Deals and strategy", "count": 6}, {"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.2% over one week, +17.3% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Innovent stock trades steadily as oncology pipeline and revenue growth support valuation"}], "updated_at": "2026-07-17T16:32:51.375003+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}